HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 05-03-2009, 09:36 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
her2 breast tumors are detectable by light because they have higher oxygen content

(are more angiogenic). Has implications for both noninvasive imaging and for selecting proper treatment (antiangiogenic agents):


Light Reveals Breast Tumor Oxygen Status

Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.

Duke University bioengineers have developed a light-based system that can quickly and easily provide important information about oxygen levels within a tumor while it is still in place. The new system, based on diffuse reflectance spectroscopy, gives researchers important clues about the tumor by interpreting how the light is either reflected back from the tumor or absorbed.

Oxygen status is important, the researchers said, since past studies have shown that low levels of oxygen, or hypoxia, are more often associated with malignant tissue than healthy normal tissue. Tumors that thrive in these low-oxygen environments tend to be more difficult to treat, the researchers said.

"We developed an easy-to-use fiber-optic probe that can provide immediate and non-destructive measurements of tumor oxygenation," said J. Quincy Brown, a fourth-year post-doctoral fellow in the laboratory of Nirmala Ramanujam, associate professor of biomedical engineering at Duke's Pratt School of Engineering. The results of the Duke experiments were published in the journal Cancer Research.

"This new approach could be an important new tool for physicians in determining the aggressiveness of a specific tumor and which therapies might work best against it," Brown said. "Since this system is compatible with commonly used biopsy needles, we could make oxygen measurements at the time of a needle biopsy, providing immediate feedback about the tumor's oxygen concentration."

In their current experiments, the researchers enrolled 35 women who were to undergo surgery for their breast cancer. Before the surgery, the researchers directed normal, UV-visible light directly through a needle at the surface of the tumor while it was still in the breast. Since the system gathers information immediately, researchers are able to take readings at multiple locations in little time.

Their main target was blood and its hemoglobin, a protein which is responsible for carrying oxygen throughout the body, as well as to tumors. While some types of breast cancer thrive in environments low in oxygen, other cancers stimulate the growth of new blood vessels to feed oxygen to the tumor.

"Our system measured how the light was either absorbed by the hemoglobin, which gave us an optical fingerprint of the oxygen status of the tumor," Brown explained. "This fingerprint can give clues about which form of therapy – chemo, radiation, surgery – might be the most effective for that particular tumor."

One interesting finding involved tumors with the gene HER2/neu. It is estimated that one in five breast cancers exhibit over-expression of the HER2/neu gene. A routinely used drug known as Herceptin, which can block HER2/neu over-expression, is only effective in treating tumors with this gene.

"The tumors that over-expressed the HER2/neu gene had significantly higher levels of oxygen," Brown said. "This is likely due to the fact that the amplification of this gene encourages the formation of tiny new blood vessels, which in turn feed the tumor. Knowing how the Her2/neu status of a tumor is affecting tumor oxygenation at the time of biopsy would be useful information for the oncologist, since over-expression of this gene typically leads to a cancer that is more aggressive and more resistant to treatment."

The researchers plan future studies of breast cancer patients undergoing chemotherapy by taking regular oxygen measurements to determine how a particular tumor is responding to therapy over time.

SOURCES:
Cancer Research, April 1, 2009
Duke University (http://www.duke.edu)
Lani is offline   Reply With Quote
Old 05-04-2009, 05:17 AM   #2
TSund
Senior Member
 
TSund's Avatar
 
Join Date: May 2007
Location: DFW area (TX)
Posts: 431
Lani,

Have you posted the research regarding bonding iron to a cancer treatment substance and thus "targeting" treatment? I read that it is promising and that there is a belief it may treat many types of cancer.
__________________
Terri, spouse of Ruth, Dallas/Ft. Worth area
Ruth dx 05/01/07 (age 50) Filipino
multifocal, several tumors .5 -2.5 cm, large area
Breast MRI showed 2 enlarged nodes, not palpable
100%ER+, 95%PR+, HER2+++
6x pre-surgery TCH chemo finished 9/15/7 Dramatic tumor shrinkage
1 year Herceptin till 6/08
MRM 10/11/07, SNB: 0/4 nodes + Path: tumors reduced to only a few "scattered cells"
now 50% ER+, PR- ???
Rads finished 1/16/08
Added Tamoxifen,
Finished Herceptin 05/08
NOW is the time to appreciate life to the fullest.
TSund is offline   Reply With Quote
Old 05-04-2009, 01:36 PM   #3
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Dr. Sam Gambhir at Stanford has been using iron nanocompounds linked to

herceptin to try to diagnose bc in mice, identify minimal residual disease and follow treatment.

It is not yet approved for use in humans. Approval for use for treatment will take longer (imaging agents need to meet simpler approval guidelines as I understand it)

I will inquire as to if/when volunteers may be requested to open opportunities for you ladies.

More later...
Lani is offline   Reply With Quote
Old 05-04-2009, 03:13 PM   #4
hutchibk
Senior Member
 
hutchibk's Avatar
 
Join Date: Oct 2005
Posts: 3,519
hmmm - I doubt this correlates directly, but I'll ask it anyway... do you think that efforts in the health community to ward off b/c by advocating more exercise and oxygenated water, designed to get more oxygen to the cells and make them stronger - could have an adverse effect if one is HER2+?
__________________
Brenda

NOV 2012 - 9 yr anniversary
JULY 2012 - 7 yr anniversary stage IV (of 50...)

Nov'03~ dX stage 2B
Dec'03~
Rt side mastectomy, Her2+, ER/PR+, 10 nodes out, one node positive
Jan'04~
Taxotere/Adria/Cytoxan x 6, NED, no Rads, Tamox. 1 year, Arimadex 3 mo., NED 14 mo.
Sept'05~
micro mets lungs/chest nodes/underarm node, Switched to Aromasin, T/C/H x 7, NED 6 months - Herceptin only
Aug'06~
micro mets chest nodes, & bone spot @ C3 neck, Added Taxol to Herceptin
Feb'07~ Genetic testing, BRCA 1&2 neg

Apr'07~
MRI - two 9mm brain mets & 5 punctates, new left chest met, & small increase of bone spot C3 neck, Stopped Aromasin
May'07~
Started Tykerb/Xeloda, no WBR for now
June'07~
MRI - stable brain mets, no new mets, 9mm spots less enhanced, CA15.3 down 45.5 to 9.3 in 10 wks, Ty/Xel working magic!
Aug'07~
MRI - brain mets shrunk half, NO NEW BRAIN METS!!, TMs stable @ 9.2
Oct'07~
PET/CT & MRI show NED
Apr'08~
scans still show NED in the head, small bone spot on right iliac crest (rear pelvic bone)
Sept'08~
MRI shows activity in brain mets, completed 5 fractions/5 consecutive days of IMRT to zap the pesky buggers
Oct'08~
dropped Xeloda, switched to tri-weekly Herceptin in combo with Tykerb, extend to tri-monthly Zometa infusion
Dec'08~
Brain MRI- 4 spots reduced to punctate size, large spot shrunk by 3mm, CT of torso clear/pelvis spot stable
June'09~
new 3-4mm left cerrebellar spot zapped with IMRT targeted rads
Sept'09~
new 6mm & 1 cm spots in pituitary/optic chiasm area. Rx= 25 days of 3D conformal fractionated targeted IMRT to the tumors.
Oct'09~
25 days of low dose 3D conformal fractionated targeted IMRT to the bone mets spot on rt. iliac crest that have been watching for 2 years. Added daily Aromasin back into treatment regimen.
Apr'10~ Brain MRI clear! But, see new small spot on adrenal gland. Change from Aromasin back to Tamoxifen.
June'10~ Tumor markers (CA15.3) dropped from 37 to 23 after one month on Tamoxifen. Continue to monitor adrenal gland spot. Remain on Tykerb/Herceptin/Tamoxifen.
Nov'10~ Radiate positive mediastinal node that was pressing on recurrent laryngeal nerve, causing paralyzed larynx and a funny voice.
Jan'11~ MRI shows possible activity or perhaps just scar tissue/necrotic increase on 3 previously treated brain spots and a pituitary spot. 5 days of IMRT on 4 spots.
Feb'11~ Enrolled in T-DM1 EAP in Denver, first treatment March 25, 2011.
Mar'11~ Finally started T-DM1 EAP in Denver at Rocky Mountain Cancer Center/Rose on Mar. 25... hallelujah.

"I would rather be anecdotally alive than statistically dead."
hutchibk is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:02 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter